Crinecerfont
As of the edition of 20 October 2026, Crinecerfont is a small molecule: marketed, first approved in 2024 (US); acts on CRHR1; US protection ends in 2043.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Crenessity
- First approved
- 13 December 2024 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Neurocrine
- Registered trials
- 7, 0 stopped early
- Disease areas
- Hormones; Inherited and neonatal; Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Mental health
US protection
US protection ends in 2043.
The last listed US drug-substance patent ends in 2043. The application that gives this date is held by Neurocrine.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product16 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 16 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Crinecerfont.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CRHR1 | Corticotropin-releasing hormone receptor 1 | P34998 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 3 | 2 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 7 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Neurocrine | Originator and Lead sponsor of trials | 2018 to now |